FCS

Showing 2 posts of 2 posts found.

NICE rules against the use of Akcea’s Waylivra in the NHS

January 3, 2020
Medical Communications Akcea, European Commission, FCS, NHS, NICE

NICE has not recommended Akcea’s drug Waylivra (volanesorsen) to be used for the treatment of Familial Chylomicronaemia Syndrome (FCS) in …

Akcea and Ionis’ Waylivra nets CHMP approval in ultra-rare familial chylomicronaemia syndrome

March 5, 2019
Manufacturing and Production, Sales and Marketing Akcea, FCS, Ionis, familial chylomicronemia syndrome, pharma, rare disease

Akcea Therapeutics and Ionis Pharmaceuticals have announced that their investigational therapy Waylivra (volanesorsen) has been recommended by the EMA’s Committee …

The Gateway to Local Adoption Series

Latest content